(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 November 2009 (19.11.2009)

PCT

(10) International Publication Number
WO 2009/138781 A1

(51) **International Patent Classification**:
A61K 31/517 (2006.01) *A61P 35/00* (2006.01)

(21) **International Application Number**:
PCT/GB2009/050496

(22) **International Filing Date**:
11 May 2009 (11.05.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/052,706 13 May 2008 (13.05.2008) US
61/110,637 3 November 2008 (03.11.2008) US

(71) **Applicant** *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) **Applicant** *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BOARDMAN, Kay, Alison** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **BURNS, Susan, Elizabeth** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **DOBSON, Andrew, Hornby** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **WHITLOCK, Brian** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB).

(74) **Agent**: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/138781 A1

(54) **Title**: FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE

(57) **Abstract**: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.